Recent microbiological studies with gentamicin.
Recent microbiological studies with gentamicin.
复制标题
最近的庆大霉素微生物学研究。
DOI：
10.1093/infdis/119.4-5.355
复制
发表时间：
1969
影响因子：
6.4
通讯作者：
Marvin J. Weinstein
中科院分区：
文献类型：
--
作者：
J. Waitz;Marvin J. Weinstein
临床上使用的庆大霉素是由3种成分组成的混合物，即庆大霉素d、da和C2[1,2]。最近，先灵公司对这些成分的化学结构进行了研究。已经发表了至少两种测定方法来确定复合物中存在的组分的比例[4,5]，并且食品和药物管理局已经批准了先灵公司为复合物中允许的每种组分的相对量建立的限量[6,7]。温斯坦和他的同事[1]提出了初步研究，证明这三种成分在体外具有几乎相同的活性。实验还表明，3种成分对金黄色葡萄球菌的急性毒性和保护作用在小鼠体内无显著差异。
The clinically available form of gentamicin is a mixture of 3 components, namely, gentamicins d, da, and C2 [1, 2]. The chemical structure of the components was studied recently at Schering Corporation [3]. At least 2 assay procedures have been published for determining the ratio of the components present in the complex [4, 5], and the Food and Drug Administration has approved limits established by Schering Corporation for the relative amounts of each of the components allowable in the complex [6, 7]. Weinstein and co-workers [1] presented initial studies which demonstrated that the 3 components have nearly identical in vitro activity. They also showed that the acute toxicity as well as the protective activity of the 3 components against Staphylococcus aureus were not significantly different in mice.